Singapore Stocks Markets

AirTrunk Singapore REIT IPO

Singapore ETF Boom: Will More Retail Investment Products Help or Hurt Investors?

/

Singapore Wants More Investment Products. The Real Risk Is Not Leverage — It Is What Investors Do With It Singapore’s plan to broaden the range of investment products available to retail investors sounds like an uncomplicated win. More choice should mean deeper markets. More ETFs should mean better access. More sophisticated products should make Singapore’s

Singapore ETF Boom: Will More Retail Investment Products Help or Hurt Investors? Read More »

Aspial Lifestyle stock,

Should Investors Buy Aspial Lifestyle Stock? The 88% Profit Surge Hides a More Interesting Investment Story

/

At first glance, Aspial Lifestyle’s latest results look like the kind of numbers that can make a small-cap stock suddenly interesting. Revenue hit a record S$464.2 million. Net profit jumped 88% to S$52.4 million. Earnings per share rose 92%. And the interim dividend increased a remarkable 125%, from S$0.004 to S$0.009 per share. But investors

Should Investors Buy Aspial Lifestyle Stock? The 88% Profit Surge Hides a More Interesting Investment Story Read More »

Capitaland China Trust

SGX’s Real Growth Story May Have Very Little to Do With Singapore IPOs

/

Singapore Exchange is one of those companies that investors can easily misunderstand precisely because they see too much of it. The familiar SGX is the exchange on which Singapore companies list, Singapore investors buy shares and Singapore brokers execute trades. The investment opportunity, however, increasingly lies elsewhere. SGX is becoming less like a traditional national

SGX’s Real Growth Story May Have Very Little to Do With Singapore IPOs Read More »

Singapore stocks 2027

Should Investors Buy Grab Stock? The Real Opportunity May Be Its Southeast Asian Super-App Flywheel

/

Grab Is No Longer Just a Ride-Hailing Company. That Changes the Investment Case Grab’s latest results contain an eye-catching number: quarterly profit reached US$252 million, more than six times the US$35 million recorded a year earlier. But that is not the number long-term investors should focus on. The more important development is happening underneath the

Should Investors Buy Grab Stock? The Real Opportunity May Be Its Southeast Asian Super-App Flywheel Read More »

DBS OCBC UOB

CapitaLand Investment Has S$7–9 Billion of Assets to Monetise. Is That Good News?

/

CapitaLand Investment’s S$7–9 billion monetisation opportunity sounds like exactly the kind of announcement investors want to hear. A company identifies billions of dollars of embedded value, sells assets that it considers non-core, recycles the proceeds into higher-return businesses and potentially returns some of the cash to shareholders. Simple enough. But there is a more uncomfortable

CapitaLand Investment Has S$7–9 Billion of Assets to Monetise. Is That Good News? Read More »

Grab Atome acquisition

Why Singapore Banks Are Courting the Next Generation of Wealthy Families?

/

The next battle for Singapore’s banks is not for deposits. It is for the heirs. Singapore’s three major banks are spending time and money teaching wealthy young adults about leadership, entrepreneurship, investing and succession. At first glance, these programmes look like corporate social responsibility initiatives or sophisticated networking events. They are neither. They are Customer-acquisition

Why Singapore Banks Are Courting the Next Generation of Wealthy Families? Read More »

Singapore stock market 2027

Should Investors Buy UltraGreen.ai After New US Competition? The Real Test Is Pricing Power

/

UltraGreen.ai’s Biggest Risk Is Not Losing Market Share — It Is Losing Pricing Power For several years, UltraGreen.ai has enjoyed something investors rarely get in healthcare: a specialised product with high margins, a dominant US market position and relatively little direct competition. That combination is now being tested. Zydus Lifesciences has received US FDA approval

Should Investors Buy UltraGreen.ai After New US Competition? The Real Test Is Pricing Power Read More »

Scroll to Top